Hospira to acquire Maybe Pharma in US$2bn deal

Published: 21-Sep-2006
Media Pharmaceutical

Hospira, global hospital products company, is to acquire Australia-based specialty injectable pharmaceuticals company Mayne Pharma.


Hospira, global hospital products company, is to acquire Australia-based specialty injectable pharmaceuticals company Mayne Pharma.

Under the terms of the agreement, Mayne shareholders will receive AUD$4.10 cash per outstanding ordinary share of Mayne, or a total equity consideration of approximately AUD$2.6bn (US$2bn), including options. The transaction represents a 32 percent premium over Mayne's Sept. 18, 2006, closing price.

'This combination will create the leading generic injectable pharmaceuticals company in the world,' said Christopher Begley, Hospira ceo.

'The Mayne acquisition more than doubles Hospira's international presence and significantly accelerates the expansion of our generic injectables business,' Begley added.

Hospira hopes that its acquisition of Mayne will accelerate Hospira's global expansion, expand and solidify Hospira's oncology presence, provide the company with potent/cytotoxic manufacturing and r&d capabilities, and increase the number and availability of generic injectable drugs in its portfolio.

'We look forward to welcoming our Mayne colleagues to Hospira and fully expect their talents and skill sets to contribute to our future success,' said Begley.

  • Companies:
  • Hospira
See more

You may also like

Drug Delivery

Mylan and Hospira voluntarily recall injectables

Read more
Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been reported as yet

Trending Articles

  1. CDMO market trends and dynamics The rise of the embedded model
  2. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  3. The rise of nutraceuticals in the pharmaceutical industry Driven by current market and consumer trends, pharmaceutical companies are increasingly embracing nutraceutical ingredients such as astaxanthin
  4. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  5. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Drug Delivery

Mylan and Hospira voluntarily recall injectables

Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been reported as yet
Regulatory

Brussels explains why it approved Pfizer/Hospira deal

Pfizer made a commitment to remove possible product overlaps between the two companies
Regulatory

Hospira calls for biosimilars to have same name as biologicals

Different names for a biologic and the biosimilar medicine patterned on that biologic could create confusion among clinicians
Research & Development

Hospira and Pfenex link up to develop Lucentis biosimilar

Pfenex will receive US$51m upfront once the collaboration receives antitrust approval
Drug Delivery

Pfizer to acquire Hospira

Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira
Regulatory

Biosimilars need the same names as original biologics

Proper naming of biosimilars is key for patient access and safety, say delegates at WHO INN meeting
Media

Asia and Latin America will drive biosimilars growth in next decade, says Visiongain

Established players will focus on monoclonal antibodies and licensing deals
Subscribe now